| 540.71 -10.51 (-1.91%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 666.4 | 1-year : | 694.97 |
| Resists | First : | 570.54 | Second : | 595.01 |
| Pivot price | 574.82 |
|||
| Supports | First : | 530.96 | Second : | 441.76 |
| MAs | MA(5) : | 566.3 |
MA(20) : | 576.71 |
| MA(100) : | 603.44 |
MA(250) : | 571.65  |
|
| MACD | MACD : | -6.7 |
Signal : | -4.1 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 32.8 |
| RSI | RSI(14): 35.8 |
|||
| 52-week | High : | 678.21 | Low : | 379.39 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARGX ] has closed below the lower bollinger band by 19.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ARGX ] is to continue within current trading range. Bollinger Bands are 28.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 550.95 - 555.44 | 555.44 - 558.45 |
| Low: | 530.93 - 535.9 | 535.9 - 539.25 |
| Close: | 534.24 - 541.89 | 541.89 - 547.04 |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Mon, 16 Jun 2025
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - argenx (NASDAQ:ARGX) - Benzinga
Wed, 11 Jun 2025
argenx (ARGX) Maintains Outperform Rating with $715 Target Price - GuruFocus
Wed, 11 Jun 2025
Argenx SE Reports Promising Phase 2 Results for Efgartigimod in Autoimmune Diseases - TipRanks
Fri, 06 Jun 2025
argenx SE (ARGX): A Bull Case Theory - Insider Monkey
Wed, 28 May 2025
Argenx SE Announces AGM Results and Key Resolutions - TipRanks
Wed, 28 May 2025
argenx Announces Results of Annual General Meeting of Shareholders - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 55.5 (%) |
| Shares Short | 2,400 (K) |
| Shares Short P.Month | 2,270 (K) |
| EPS | 16.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 90.48 |
| Profit Margin | 40.2 % |
| Operating Margin | 17.5 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 95.6 % |
| Gross Profit (p.s.) | 21.45 |
| Sales Per Share | 43.23 |
| EBITDA (p.s.) | 3.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 32.95 |
| PEG Ratio | 0 |
| Price to Book value | 5.97 |
| Price to Sales | 12.5 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|